These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33911470)

  • 1. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
    Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
    World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
    Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
    J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
    Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
    Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
    Liu Y; Jia M; Wu S; Jiang W; Feng Y
    Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
    Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
    Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
    Song MJ; Song DS; Kim HY; Yoo SH; Bae SH; Choi JY; Yoon SK; Paik YH; Lee JS; Lee HW; Kim HJ
    World J Gastroenterol; 2012 Nov; 18(43):6277-83. PubMed ID: 23180949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
    Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
    Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.
    Wang ML; Chen EQ; Tao CM; Zhou TY; Liao J; Zhang DM; Wang J; Tang H
    Scand J Gastroenterol; 2017 Dec; 52(12):1420-1426. PubMed ID: 28880694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients.
    Gao L; Hu Y; Shi X; Li X; Zhang D; Ren H
    Ann Hepatol; 2020; 19(3):329-334. PubMed ID: 31884016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review.
    Liu J; Li T; Zhang L; Xu A
    Hepatology; 2019 Sep; 70(3):1045-1055. PubMed ID: 30561829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial.
    Zhou Y; Yan R; Ru GQ; Yu LL; Yao J; Wang H
    Hepatol Int; 2019 Jul; 13(4):422-430. PubMed ID: 31172416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
    Chen H; Ding X; Liao G; Xia M; Ren Z; Fan R; Peng J
    J Viral Hepat; 2021 Aug; 28(8):1121-1129. PubMed ID: 33899998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
    Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
    Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.
    Sun T; Qiu Y; Wang T; Yang Y; Qiu H; Shen S; Pang H; Wang W
    Cancer Med; 2024 Aug; 13(16):e70185. PubMed ID: 39219190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When can we stop nucleoside analogues in patients with chronic hepatitis B?
    Chong CH; Lim SG
    Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.